CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 122 enrolled
Drug / intervention
68Ga-DOTATOC PET/CTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02441062
NCT02441062Phase 2Completed
CompareCT.gov

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Sue O'Dorisio·interventional·Posted May 12, 2015·Updated Dec 21, 2020

In Brief

A Phase 2 clinical trial evaluating 68Ga-DOTATOC PET/CT for Neuroendocrine Tumors and 3 related conditions. Completed, enrolled 122 participants across 1 site.

Detailed Summary

Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
CountriesUnited States
CollaboratorsUniversity of Iowa

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 12, 2015
Enrollment StartSep 1, 2015
Primary CompletionJan 20, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 11.1 years ago

Interventions

68Ga-DOTATOC PET/CTdrug

Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors